Sodium-glucose cotransporter-2 (SGLT2) inhibitors may reduce the risk of recurrent flares, emergency department visits, and hospitalizations in patients with gout, according to a new study published by McCormick et al in the Annals of Internal Medicine. Investigators compared the outcomes of patients with gout who were treated with either SGLT2 inhibitors or dipeptidyl peptidase 4 (DPP-4) inhibitors from 2014 to 2022. The primary outcome was the incidence of recurrent gout flares. Patients who received SGLT2 inhibitors experienced a flare rate of 52.4 per 1,000 person-years vs 79.7 per 1,000 person-years among patients who received DPP-4 inhibitors (rate ratio [RR] = 0.66, 95% confidence interval [CI] = 0.57–0.75). Further, compared with those who received DPP-4 inhibitors, patients who received SGLT2 inhibitors were less likely to have a gout-related emergency department visit or hospitalization (RR = 0.52, 95% CI = 0.32–0.84), and demonstrated a decreased risk of myocardial infarction (hazard ratio [HR] = 0.69, 95% CI = 0.54–0.88) and stroke (HR = 0.81, 95% CI = 0.62–1.05). However, there were no statistically significant differences in the risk of osteoarthritis between the two groups, and the risk of genital infections was higher among those who received SGLT2 inhibitors (HR = 2.15, 95% CI = 1.39–3.30). The investigators concluded that SGLT2 inhibitors may be promising treatment options for patients with gout.